Organization
Zhongda Hospital, Southeast University
4 abstracts
Abstract
Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations.Org: State Key Laboratory of Molecular Oncology, National Clinical Research Center for Cancer, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Chest Hospital, Capital Medical University, Beijing, China, Liaoning Cancer Hospital,
Abstract
A cross-sectional study of synchronous liver metastasis in patients with gastric cancer.Org: Zhongda Hospital, Southeast University, Medical School of University, Southeast University, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Efficacy and safety of anlotinib in overall and disease-specific advanced gynecological cancer: A real-world study.Org: Southeast University, Zhongda Hospital, Southeast University, Tumor Hospital Affiliated to Nantong University, Jiangsu Cancer Hopital, Xuzhou Central Hospital,
Abstract
Real-world data from a multi-center study: Insights to the efficacy and safety in patients with ovarian cancer (OC) received niraparib as first-line (1st-L) maintenance therapy (MT).Org: Zhongda Hospital, Southeast University, School of Medicine, Zhejiang University, Hangzhou, China, University of Science and Technology of China, Fudan University (Xiamen Branch), Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research,